AstraZeneca shares fall after HSBC downgrade

The news headline indicates that HSBC's downgrade is weighing on the stock. Technical indicators support the decline: RSI at 24.5 is in oversold territory, MACD is below the signal line and negative, and the price is trading below both the 20-day and 50-day moving averages. The sharp 11% drop in the last 24 hours suggests selling pressure may persist. A short-term recovery appears unlikely, though some bargain buying could emerge due to oversold conditions.

HSBC's downgrade of AstraZeneca shares could create negative sentiment for the bank's own stock. Technical indicators suggest the stock is approaching overbought territory in the short term (RSI at 63), with weakening momentum. Although the MACD remains positive, its convergence with the signal line indicates a slowdown in upward momentum. While the last closing price above the 20- and 50-day moving averages supports the medium-term trend, the news flow may increase selling pressure in the short term. Therefore, a slight decline is expected over the next 1-3 days.